Personal genomics startup 23andMe has recently raised another $14.2 million to close out its $27.8 million Series B round, according to regulatory filings with the SEC. The filing indicates that the new funding is an amendment to the company’s previously reported raise of $11 million in May, which was followed by an additional $2.6 million in June. We’ve reached out to 23andMe to confirm the funding amount, and to also determine if there are any new investors. Update: 23andMe have confirmed that they’ve raised funding, but have not yet confirmed the amount.
The last few months have been rocky for the company. In September, co-founder Linda Avey left 23andMe to start a foundation dedicated to studying Alzheimer’s disease. In late October, the company laid off a substantial chunk of its workforce, but declined to comment on how many people were affected.
23andMe is one of the first personal genomics companies, allowing customers to have portions of their DNA analyzed for around $400 (there are a few different products available). After completing a test, customers can log into the site to get reports on their genetic makeup, including a listing of some diseases they may be at risk for.